Jim Tananbaum is the founder and Chief Executive Officer of Foresite Capital. He restructured Foresite to a healthcare private equity firm. The firm specialized in, identifying emerging healthcare leaders, supplying capital, providing information resources and networks. Before he founded Foresite Capital, Tananbaum had co-founded two healthcare investment practices and biopharmaceutical companies. He started GelTex Pharmaceuticals which did so well and brought two types of drugs to the global market. He was also the CEO of Theravance, Inc which worked jointly with Innoviva. The two companies have dominated the market making approximately $3.2 billion.
Jim has had many investment experiences including the partner of Prospect Venture, Partner II and III. Earlier in his career, he partnered with Sierra Venture. At Sierra Venture, he established healthcare investment practices. Jim has worked with other investments namely Amira Pharmaceuticals, Amerigroup, Healtheon, and Jazz Pharmaceuticals. When Jim Tananbaum founded Foresite Capital, he had a vision of bringing together all aspects of his career and experience in the creation of a better investment platform.
Since his time in high school, Jim had passion in integrating disciplines, such as hard sciences and computer science with health science. He has an excellent educational background. Jim majored in Math and Electrical Engineering/Computer Science at Yale University. He holds M.D and Masters in Business Administration from Harvard University. He also pursued M.S at the Massachusetts Institute of Technology.
Jim has led numerous investments in over 21 successful healthcare companies. He is leading in both entrepreneurs and academician’s fields. As an investment strategist and a healthcare entrepreneur, he did not put much effort to start Foresite Capital. Currently, Foresite Company has invested in over 77 different healthcare companies in diagnostics, medical services, genomic sequencing, and biopharmaceuticals. The company has invested in Aeri Pharmaceuticals, Aimmune Therapeutics, Intarcia Therapeutics and 10x Genomics. Moreover, he is committed to providing the best healthcare services in the world. Jim works mostly with his team to ensure they meet their objectives in service delivery.
Although Foresite received its first capital in the year 2013, Foresite Capital has sponsored various diverse healthcare leaders in Pharmaceuticals, gene sequencing, synthetic biology, data science and healthcare delivery. In 2017, he featured in Forbes magazine which released a Midas list with top 100 technology venture capital investors. More details can be found on Crunchbase.